Kaplan Fox Alerts Investors of Capricor Therapeutics, Inc. (CAPR) to a Pending Securities Class Action - Deadline is September 28, 2026
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Capricor Therapeutics on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The complaint alleges that Capricor made changes to the statistical analysis plan for its Dermamiocel BLA without FDA agreement, coinciding with a reported 64% drop in the stock price on July 27, 2026.
Key figures
- Class period end
- July 26, 2026
- Stock drop amount
- $12.70
- Class period start
- December 17, 2025
- Stock drop percent
- 64%
- Closing price after drop
- $7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.